# Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects

> **NCT00837356** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 23 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Haemophilia A

## Interventions

- **DRUG:** Advate®
- **DRUG:** turoctocog alfa

## Key facts

- **NCT ID:** NCT00837356
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00837356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00837356, "Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00837356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*